Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2015 | case report | Ausgabe 17-18/2015

Wiener klinische Wochenschrift 17-18/2015

Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature

Zeitschrift:
Wiener klinische Wochenschrift > Ausgabe 17-18/2015
Autor:
PharmD, PhD Matej Štuhec

Summary

Objective

In this case report, we describe a case in which the clinical pharmacy team was asked to provide recommendations on possible continued use of combination antidepressants in a 62-year-old Slovenian female patient with major depressive disorder following agomelatine and duloxetine hydrochloride-induced excessive sweating. When agomelatine was administered as an additional treatment, drug-induced excessive sweating was observed after a daily intake of 90 mg of duloxetine hydrochloride and 25 mg of agomelatine. After thorough discussion, it was decided not to rechallenge with agomelatine because of the serious adverse effect. After agomelatine discontinuation and switching to trazodone, symptoms immediately improved.

Discussion

Duloxetine hydrochloride-induced sweating has been reported frequently, but excessive sweating induced by agomelatine and duloxetine hydrochloride has not been reported in the literature. The adverse effect was determined by a clinical pharmacist using the Naranjo probability scale and was probably associated with agomelatine use (6 points) and possibly associated with duloxetine hydrochloride use (4 points). The exact mechanism for this adverse effect in this patient is not known, but we believe that a pharmacodynamic drug–drug interaction between agomelatine and duloxetine hydrochloride had occurred.

Conclusion

Such a case has not yet been described in literature; however, an adverse effect associated with drug–drug interaction can occur, as this report clearly demonstrates. The benefits of this antidepressant combination need to be carefully balanced with the risks associated with its use. This case report also highlights the increased potential for adverse reactions when prescribing antidepressant combinations and importance of clinical pharmacists’ involvement in the psychiatric patients’ pharmacotherapy.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 17-18/2015

Wiener klinische Wochenschrift 17-18/2015 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungen

mitteilungen der gesellschaft

ÖGIM FLIP